Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 39INDUSTRY 32UNKNOWN 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11Radiotherapy, Intensity-Modulated 9apatinib 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Drug Therapy 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Pemetrexed 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
UNKNOWN × Interventional × icotinib × Clear all
NCT02960607 2016-11-18

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

ChineseAMS

Phase 2 Unknown
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02961270 2016-11-11

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

ChineseAMS

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡